Andy Waldeck is a managing directory for strategy and innovation at Huron and a Senior Partner at Innosight, where he leads the healthcare practice. Over the past ten years at Innosight, Andy has advised senior leaders at companies such as Aetna, Baxter, Covidien (now part of Medtronic) and Walgreens. He has extensive experience across the healthcare industry including, payers, providers, medical devices, pharmaceuticals, pharmacy and health information technology.
At Innosight, Andy’s work focuses on helping clients to develop long-term growth strategies, manage enterprise transformation, build enduring growth and innovation capabilities and design new disruptive growth businesses. In addition to his work leading the healthcare practice, Andy also has worked with other Fortune 500 companies across the media, financial services and consumer industries. Andy is a frequent speaker and author on topics of healthcare transformation, disruption and long-term growth.
Andy’s experience with growth and innovation stems from his past work with early-stage growth companies as both an investment banker and venture capitalist. Prior to joining Innosight, Andy was a Managing Director at the investment bank C.E. Unterberg, Towbin, where he completed 50 financial and strategic transactions totaling over $5B in transaction value. Most recently, Andy was a Vice President at GrandBanks Capital, an early stage IT-focused venture capital fund.
"Health for Hire: Unleashing Patient Potential to Reduce Chronic Disease Costs", Harvard Business Review, 2017
"How Disruption Can Finally Revolutionize Health Care", Harvard Business Review, 2017
"Knowing When to Reinvent", Harvard Business Review, 2015
"The New M&A Playbook", Harvard Business Review, 2011
Strategy and Innovation
MBA, with distinction, Dartmouth College, Tuck School of Business
BA, Business Economics, Brown University